In this video, Gareth J. Morgan, MD, discusses the new biologic advances in multiple myeloma and how they are currently being applied to clinical practice.
Gareth J. Morgan, MD, of the University of Arkansas for Medical Sciences in Little Rock, Arkansas, discusses the biologic advances in multiple myeloma, and how identified mutations and pathways can offer opportunities for patients to receive targeted therapies.
Dr. Morgan gave a presentation during an education session at the 2017 ASCO Meeting entitled, "Are We Integrating Biologic Advances in Multiple Myeloma Into Clinical Practice"?
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Similar Splenic, Symptom Responses Are Reported With Ruxolitinib Combos in Myelofibrosis With Anemia
June 13th 2025Results of a post hoc analysis found spleen and symptom response rates to be comparable with ESAs or danazol in combination with ruxolitinib for patients with myelofibrosis who have anemia.